Optometrists in White Salmon, WA Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Dr. Alex Baldwin, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 950 E Jewett Blvd, White Salmon, WA 98672 Phone: 509-493-2020 Fax: 509-493-2023 |
 Dr. Deborah K Sneed, O. D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 950 E Jewett Blvd., White Salmon, WA 98672 Phone: 509-493-2020 Fax: 509-493-2023 |
 White Salmon Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 950 E Jewett Blvd, White Salmon, WA 98672 Phone: 509-493-2020 Fax: 509-493-2023 |
News Archive
Same-sex couples just as committed in relationships as heterosexual couples
Their finding disputes the stereotype that couples in same-sex relationships are not as committed as their heterosexual counterparts and are therefore not as psychologically healthy.
Crizotinib may be effective treatment option for NSCLC subtype
Phase I trial results show that the chemotherapy drug crizotinib may be fast-acting and produce long-lasting treatment responses in patients with anaplastic lymphoma receptor tyrosine kinase-positive non-small-cell lung cancer.
Merck acquires Millipore for $7.0 billion
Merck KGaA, a global pharmaceutical and chemical company, today announced the successful completion of its acquisition of Millipore Corporation, a leading Life Science company based in Billerica, Massachusetts, USA, for an aggregate purchase price including debt and cash of approximately $7.0 billion. Merck agreed to acquire Millipore on February 28, 2010 for $107 in cash per share of Millipore common stock.
Scientists discover two new compounds that could help treat CF patients having common mutation
Cystic fibrosis is a lethal genetic disorder that in France affects one child per 4,500 births. An international team led by scientists at the Institut Fédératif de Recherche Necker-Enfants Malades (CNRS/Inserm/Université Paris Descartes), led by Aleksander Edelman, has recently discovered two new compounds that could be used to treat patients carrying the most common mutation.
Cardio3 BioSciences reports absence of short term adverse events in first patient following NKG2D CAR T-cell infusion
Cardio3 BioSciences, soon to be renamed Celyad, a leader in engineered cell-therapy treatments today announced the infusion of the first patient enrolled in the Company's Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-cell therapy, in cancer patients suffering from acute myeloid leukemia (AML) or multiple myeloma (MM).
› Verified 8 days ago
Physical Therapists
Chiropractors
Speech-Language Pathologists
Optometrists
Occupational Therapists